Captor Therapeutics S.A. - Asset Resilience Ratio

Latest as of September 2025: 71.95%

Captor Therapeutics S.A. (CTX) has an Asset Resilience Ratio of 71.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

zł32.05 Million

≈ $8.82 Million USD Cash + Short-term Investments

Total Assets

zł44.54 Million

≈ $12.26 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Captor Therapeutics S.A.'s Asset Resilience Ratio has changed over time. Check Captor Therapeutics S.A. (CTX) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Captor Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CTX market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	zł0.00	0%
Short-term Investments	zł32.05 Million	71.95%
Total Liquid Assets	zł32.05 Million	71.95%

Asset Resilience Insights

Very High Liquidity: Captor Therapeutics S.A. maintains exceptional liquid asset reserves at 71.95% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Captor Therapeutics S.A. Industry Peers by Asset Resilience Ratio

Compare Captor Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Captor Therapeutics S.A. (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Captor Therapeutics S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	17.57%	zł19.85 Million ≈ $5.46 Million	zł113.00 Million ≈ $31.10 Million	--

pp = percentage points

About Captor Therapeutics S.A.

WAR:CTX Poland Biotechnology

Market Cap

$112.49 Million

zł408.75 Million PLN

Market Cap Rank

#18694 Global

#143 in Poland

Share Price

zł74.20

Change (1 day)

+0.00%

52-Week Range

zł34.60 - zł87.60

All Time High

zł202.00